Regorafenib Pathway, Pharmacodynamics

No Pathway Network information available for Regorafenib Pathway, Pharmacodynamics

Pathways in the Regorafenib Pathway, Pharmacodynamics SuperPath

#	Name	Source	Genes
1	Regorafenib Pathway, Pharmacodynamics	PharmGKB	BRAF FLT1 FLT4 KDR KIT RAF1 RET TEK (see all 8) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	RET	Ret Proto-Oncogene	Protein Coding	1
2	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
3	TEK	TEK Receptor Tyrosine Kinase	Protein Coding	1
4	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
5	KDR	Kinase Insert Domain Receptor	Protein Coding	1
6	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	1
7	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	1
8	FLT4	Fms Related Receptor Tyrosine Kinase 4	Protein Coding	1

Disorders associated with Regorafenib Pathway, Pharmacodynamics SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Tetralogy of fallot	Enrichment	FLT4, KDR, RET	6.46
2	Noonan syndrome with multiple lentigines	Enrichment	BRAF, RAF1	5.74
3	Hemangioma, capillary infantile	Enrichment	FLT4, KDR	5.34
4	Pilomyxoid astrocytoma	Enrichment	BRAF, RAF1	5.20
5	Melanocytic nevus syndrome, congenital	Enrichment	BRAF, RAF1	5.07
6	Ventricular septal defect	Enrichment	BRAF, TEK	4.96
7	Lip and oral cavity carcinoma	Enrichment	BRAF, KIT	4.70
8	Noonan syndrome and noonan-related syndrome	Enrichment	BRAF, RAF1	4.50
9	Noonan syndrome 1	Enrichment	BRAF, RAF1	4.12
10	Rasopathy	Enrichment	BRAF, RAF1	4.01
11	Differentiated thyroid carcinoma	Enrichment	BRAF, RET	3.91
12	Multiple endocrine neoplasia, type iib	Enrichment	RET	3.23
13	Noonan syndrome 5	Enrichment	RAF1	3.23
14	Mastocytosis, cutaneous	Enrichment	KIT	3.23
15	Noonan syndrome 7	Enrichment	BRAF	3.23
16	Leopard syndrome 3	Enrichment	BRAF	3.23
17	Cardiomyopathy, dilated, 1nn	Enrichment	RAF1	3.23
18	Venous malformations, multiple cutaneous and mucosal	Enrichment	TEK	3.23
19	Lymphangioma	Enrichment	BRAF	3.23
20	Phace association	Enrichment	BRAF	3.23
21	Leopard syndrome 2	Enrichment	RAF1	3.23
22	Congenital heart defects, multiple types, 7	Enrichment	FLT4	3.23
23	Glaucoma 3, primary congenital, e	Enrichment	TEK	3.23
24	Chronic mast cell leukemia	Enrichment	KIT	3.23
25	Trigonitis	Enrichment	RAF1	3.23
26	Tufted angioma of skin	Enrichment	KDR	3.23
27	Bockenheimer syndrome	Enrichment	TEK	3.23
28	Isolated bone marrow mastocytosis	Enrichment	KIT	3.23
29	Thyroid cancer	Enrichment	RET	3.23
30	Smoldering systemic mastocytosis	Enrichment	KIT	3.23
31	Mastocytosis	Enrichment	KIT	3.23
32	Syringocystadenoma papilliferum	Enrichment	BRAF	3.23
33	Ganglioglioma	Enrichment	BRAF	3.23
34	Cutaneous mastocytoma	Enrichment	KIT	3.23
35	Nongerminomatous germ cell tumor	Enrichment	BRAF	3.23
36	Phace syndrome	Enrichment	BRAF	3.23
37	Typical urticaria pigmentosa	Enrichment	KIT	3.23
38	Classic hairy cell leukemia	Enrichment	BRAF	3.23
39	Nodular urticaria pigmentosa	Enrichment	KIT	3.23
40	Pseudoxanthomatous diffuse cutaneous mastocytosis	Enrichment	KIT	3.23
41	Telangiectasia macularis eruptiva perstans	Enrichment	KIT	3.23
42	Acute mast cell leukemia	Enrichment	KIT	3.23
43	Plaque-form urticaria pigmentosa	Enrichment	KIT	3.23
44	Bullous diffuse cutaneous mastocytosis	Enrichment	KIT	3.23
45	Gastrointestinal system disease	Enrichment	RET	3.23
46	Multiple endocrine neoplasia	Enrichment	RET	3.23
47	Testis seminoma	Enrichment	KIT	3.23
48	Dilated cardiomyopathy	Enrichment	BRAF, RAF1	3.03
49	Colorectal cancer	Enrichment	BRAF, RET	2.95
50	Lymphatic malformation 1	Enrichment	FLT4	2.93
51	Blue rubber bleb nevus	Enrichment	TEK	2.93
52	Intracranial hypertension, idiopathic	Enrichment	FLT4	2.93
53	Pulmonic stenosis	Enrichment	BRAF	2.93
54	Piebald trait	Enrichment	KIT	2.93
55	Angioma, tufted	Enrichment	KDR	2.93
56	Medullary thyroid carcinoma	Enrichment	RET	2.93
57	Hereditary lymphedema i	Enrichment	FLT4	2.93
58	B-lymphoblastic leukemia/lymphoma with t	Enrichment	KIT	2.93
59	Ovarian cancer	Enrichment	KIT, RET	2.83
60	Thyroid carcinoma, familial medullary	Enrichment	RET	2.75
61	Ataxia-telangiectasia	Enrichment	BRAF	2.75
62	Langerhans cell histiocytosis	Enrichment	BRAF	2.75
63	Tethered spinal cord syndrome	Enrichment	BRAF	2.75
64	Testicular germ cell cancer	Enrichment	KIT	2.75
65	Gingival overgrowth	Enrichment	RET	2.75
66	Cardiofaciocutaneous syndrome 1	Enrichment	BRAF	2.63
67	Thyroid cancer, nonmedullary, 1	Enrichment	BRAF	2.63
68	Glaucoma 3, primary infantile, b	Enrichment	TEK	2.63
69	Central hypoventilation syndrome, congenital, 1	Enrichment	RET	2.63
70	Cardiofaciocutaneous syndrome	Enrichment	BRAF	2.63
71	Craniopharyngioma	Enrichment	BRAF	2.63
72	Newborn respiratory distress syndrome	Enrichment	BRAF	2.63
73	Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	Enrichment	KIT	2.63
74	Systemic mastocytosis with associated hematologic neoplasm	Enrichment	KIT	2.63
75	Haddad syndrome	Enrichment	RET	2.63
76	Inherited cancer-predisposing syndrome	Enrichment	KIT, RET	2.60
77	Multiple endocrine neoplasia, type iia	Enrichment	RET	2.53
78	Pre-eclampsia	Enrichment	FLT1	2.53
79	Acute myeloid leukemia with maturation	Enrichment	KIT	2.53
80	Acute myeloid leukemia with t(8;21)(q22;q22) translocation	Enrichment	KIT	2.53
81	Testicular germ cell tumor	Enrichment	KIT	2.45
82	Wilms tumor 5	Enrichment	BRAF	2.45
83	Sporadic pheochromocytoma/secreting paraganglioma	Enrichment	RET	2.45
84	Thyroid cancer, nonmedullary, 2	Enrichment	BRAF	2.38
85	Glaucoma 3, primary congenital, a	Enrichment	TEK	2.38
86	Gastrointestinal stromal tumor	Enrichment	KIT	2.38
87	Noonan syndrome 3	Enrichment	RAF1	2.38
88	Gallbladder cancer	Enrichment	BRAF	2.38
89	Follicular thyroid carcinoma	Enrichment	BRAF	2.38
90	Renal hypodysplasia/aplasia 1	Enrichment	RET	2.33
91	Lymphoma, non-hodgkin, familial	Enrichment	BRAF	2.33
92	Hypothyroidism	Enrichment	RET	2.33
93	Cardiomyopathy, familial hypertrophic, 4	Enrichment	BRAF	2.28
94	Arteriovenous malformation	Enrichment	TEK	2.28
95	Congenital central hypoventilation syndrome	Enrichment	RET	2.28
96	Primary hyperaldosteronism	Enrichment	BRAF	2.28
97	Renal agenesis, bilateral	Enrichment	RET	2.28
98	Myopathy, x-linked, with excessive autophagy	Enrichment	TEK	2.23
99	Melanoma	Enrichment	BRAF	2.23
100	Lung non-small cell carcinoma	Enrichment	BRAF	2.19
101	Renal hypodysplasia/aplasia 3	Enrichment	RET	2.15
102	Pheochromocytoma	Enrichment	RET	2.08
103	Lung cancer susceptibility 3	Enrichment	BRAF	2.08
104	Wilms tumor 1	Enrichment	BRAF	2.05
105	Melanoma, cutaneous malignant 1	Enrichment	BRAF	2.00
106	Dandy-walker syndrome	Enrichment	BRAF	2.00
107	Arteriovenous malformations of the brain	Enrichment	BRAF	1.95
108	Diffuse large b-cell lymphoma	Enrichment	BRAF	1.95
109	Hereditary paraganglioma-pheochromocytoma syndromes	Enrichment	RET	1.91
110	Hepatocellular carcinoma	Enrichment	RET	1.89
111	Cardiomyopathy, familial hypertrophic, 1	Enrichment	RAF1	1.85
112	Hydrops fetalis, nonimmune	Enrichment	FLT4	1.82
113	Hirschsprung disease 1	Enrichment	RET	1.77
114	Non-immune hydrops fetalis	Enrichment	FLT4	1.74
115	Lung cancer	Enrichment	BRAF	1.73
116	Familial hypertrophic cardiomyopathy	Enrichment	RAF1	1.71
117	Left ventricular noncompaction	Enrichment	RAF1	1.69
118	Leukemia, acute myeloid	Enrichment	KIT	1.63
119	Hereditary breast carcinoma	Enrichment	RET	1.59
120	Sensorineural hearing loss	Enrichment	RET	1.55
121	Hypertelorism	Enrichment	RET	1.52
122	Familial isolated dilated cardiomyopathy	Enrichment	RAF1	1.51
123	Myeloma, multiple	Enrichment	BRAF	1.49
124	Primary ovarian insufficiency	Enrichment	KDR	1.46
125	Breast cancer	Enrichment	RET	1.36

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Regorafenib Pathway, Pharmacodynamics

Pathway Network for Regorafenib Pathway, Pharmacodynamics

Member Pathways for Regorafenib Pathway, Pharmacodynamics

Pathways in the Regorafenib Pathway, Pharmacodynamics SuperPath

Associated Genes for Regorafenib Pathway, Pharmacodynamics

Associated Disorders for Regorafenib Pathway, Pharmacodynamics

Disorders associated with Regorafenib Pathway, Pharmacodynamics SuperPath

STRING Interaction Network for Regorafenib Pathway, Pharmacodynamics

Sources for Regorafenib Pathway, Pharmacodynamics